<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414294</url>
  </required_header>
  <id_info>
    <org_study_id>K-755-1.01AU</org_study_id>
    <nct_id>NCT03414294</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of K-755 in Healthy Volunteers</brief_title>
  <official_title>A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study to Investigate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of K-755 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study designed to explore the safety, tolerability and pharmacokinetics of
      K-755 following oral administration to healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">February 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Sequential Assignment/Crossover (for food effect)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Masking for Part A (SAD) and Part B (MAD), open for Part C (FE)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A, B and C: Incidence and severity of Adverse Events</measure>
    <time_frame>Up to 28 days after last administration</time_frame>
    <description>A treatment-emergent adverse events (TEAE) will be summarized by treatment and overall, and summarized for each treatment by severity and relationship to study drug. All TEAEs leading to withdrawal, or SAEs, will be summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, B and C: Number of subjects with clinical laboratory test abnormalities</measure>
    <time_frame>Up to 28 days after last administration</time_frame>
    <description>The clinical laboratory will include hematology (hematocrit, hemoglobin, mean cell hemoglobin, mean cell hemoglobin concentration, mean cell volume, platelet count, red blood cell count, white blood cell count), clinical chemistry (alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, calcium, chloride, cholesterol, creatinine, creatine phosphokinase, direct bilirubin, estimated glomerular filtration rate, gamma glutamyl transferase, glucose. inorganic phosphate, iron, lactate dehydrogenase, phosphorus, potassium, sodium, total bilirubin, total CO2, total protein, triglyceride, urea, uric acid), and urinalysis (bilirubin, blood, color and appearance, glucose, ketones, leukocyte esterase, nitrite, pH, protein, specific gravity, urobilinogen, microscopic examination, electrolytes). Abnormality will be determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, B and C: Number of subjects with vital signs abnormalities</measure>
    <time_frame>Up to 28 days after last administration</time_frame>
    <description>The vital sign will include blood pressure (mmHg), pulse rate (bpm), respiratory rate (breaths/min), and body temperature (degree Celsius). Abnormality will be determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, B and C: Number of subjects with clinically significant change in body weight</measure>
    <time_frame>Up to 28 days after last administration</time_frame>
    <description>Change in body weight (kg) at baseline and post dose will be measured. Clinical significance will be determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A, B and C: Number of subjects with abnormal findings in physical examinations</measure>
    <time_frame>Up to 28 days after last administration</time_frame>
    <description>The physical examination will typically include general appearance, head and neck, eyes, ear, nose and throat, lymph nodes, thyroid, cardiovascular, respiratory, abdomen, nervous, skin, musculoskeletal, peripheral vascular and extremities and be performed at Investigator's discretion based on reported symptoms. Abnormality will be determined by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: AUC0-inf of K-755</measure>
    <time_frame>Up to 28 days after single administration</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: AUC0-tlast of K-755</measure>
    <time_frame>Up to 28 days after single administration</time_frame>
    <description>AUC from time zero to the time of the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Cmax of K-755</measure>
    <time_frame>Up to 28 days after single administration</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Tmax of K-755</measure>
    <time_frame>Up to 28 days after single administration</time_frame>
    <description>Time of the observed maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: t1/2 of K-755</measure>
    <time_frame>Up to 28 days after single administration</time_frame>
    <description>Terminal plasma elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: AUC0-Ï„ of K-755</measure>
    <time_frame>Up to 28 days after repeated administration</time_frame>
    <description>AUC over the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Cmax of K-755</measure>
    <time_frame>Up to 28 days after repeated administration</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Tmax of K-755</measure>
    <time_frame>Up to 28 days after repeated administration</time_frame>
    <description>Time of the observed maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: t1/2 of K-755</measure>
    <time_frame>Up to 28 days after repeated administration</time_frame>
    <description>Terminal plasma elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: AUC0-inf of K-755</measure>
    <time_frame>Up to 7 days after single administration</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: AUC0-tlast of K-755</measure>
    <time_frame>Up to 7 days after single administration</time_frame>
    <description>AUC from time zero to the time of the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Cmax of K-755</measure>
    <time_frame>Up to 7 days after single administration</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Tmax of K-755</measure>
    <time_frame>Up to 7 days after single administration</time_frame>
    <description>Time of the observed maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: t1/2 of K-755</measure>
    <time_frame>Up to 7 days after single administration</time_frame>
    <description>Terminal plasma elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>K-755 Part A (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part A (SAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>K-755 Part B (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part B (MAD)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>K-755 Part C (FE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-755 Part A (SAD)</intervention_name>
    <description>Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.</description>
    <arm_group_label>K-755 Part A (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part A (SAD)</intervention_name>
    <description>Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.</description>
    <arm_group_label>Placebo Part A (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-755 Part B (MAD)</intervention_name>
    <description>Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.</description>
    <arm_group_label>K-755 Part B (MAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part B (MAD)</intervention_name>
    <description>Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.</description>
    <arm_group_label>Placebo Part B (MAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-755 Part C (FE)</intervention_name>
    <description>Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.</description>
    <arm_group_label>K-755 Part C (FE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

          2. Males or females, of any race, between 18 and 45 years of age.

          3. Body mass index (BMI) between 18.0 and 28.0 kg/m2.

          4. Hematology, clinical chemistry, and urinalysis test results within the reference
             ranges or showing no clinically relevant deviations, as judged by the Investigator.

          5. No clinically significant abnormalities on the basis of medical history, physical
             examination findings, and vital signs.

          6. All females must have a negative serum pregnancy test.

          7. Able and willing to comply with the protocol and study procedures.

        Exclusion Criteria:

          1. Female subject who are pregnant or breastfeeding.

          2. Subject with presence of active or recurring clinically significant cardiovascular,
             pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic,
             hematologic, gastrointestinal, or metabolic disease requiring medical treatment.

          3. Subject with any surgical or medical condition that might significantly alter the
             absorption, distribution, metabolism, or excretion of K-755.

          4. Subject with presence of an active malignancy or within the past 5 years a malignancy
             of any type, other than basal cell carcinoma of the skin.

          5. Subject has a history of type 1 hypersensitivity to any medication and/or clinically
             relevant food allergies.

          6. Subject has a history of drug addiction.

          7. Subject has a positive screen for drugs of abuse, cotinine or alcohol.

          8. Subject has a history of regular alcohol consumption within 6 months of the study.

          9. Subject has smoked tobacco within 6 months prior to Check-in, or has used non-inhaled
             tobacco- or nicotine-containing products within 3 months prior to Check-in.

         10. Subject has used prescription or over-the-counter medications, dietary/nutritional
             supplements (except paracetamol or vitamin supplements)

         11. Subject has used steroid medications (oral, inhaled, parenteral, or topical) within 30
             days or 5 half-lives (whichever is longer) before study drug administration.

         12. Subject has participated in an investigational drug study within 30 days or 5
             half-lives (whichever is longer) before study drug administration.

         13. Subject has a positive screen for hepatitis B surface antigen, hepatitis C virus
             antibody, or human immunodeficiency virus types 1 and 2 antigens/antibodies.

         14. Subject has had a clinically significant acute illness within 4 weeks or other illness
             within 5 days before the first study drug administration.

         15. Subject or a family member of the subject is a member of the professional or ancillary
             personnel working at the investigative site involved in the study.

         16. Not suitable for entry into the study in the opinion of the Investigator.

         17. Receipt of blood products within 2 months prior to Check-in.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jamie Baker</last_name>
    <phone>+61 8 7088 4938</phone>
    <email>jamie.baker@cmax.com.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX, Clinical Research Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

